Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Immunotherapies continue to show promise in this landscape, with the results of the ONO-4538-12 trial demonstrating the activity of nivolumab (Opdivo) in patients with unresectable advanced or recurrent gastric cancer.

Al-Batran says that the emergence of these new agents in immunotherapy will hopefully improve survival in this disease.

Videos

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research&mdash;Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Dr. Al-Batran on Future of Treatment in Gastric Cancer

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research — Frankfurt, Germany, discusses the results of trial combining everolimus (Afinitor) with paclitaxel in the treatment of patients with gastric cancer.

This was a randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).

The study aimed to improve outcomes of patients by adding everolimus to paclitaxel chemotherapy in patients who have received prior lines of chemotherapy. Those with gastric cancer were administered either paclitaxel plus everolimus or paclitaxel monotherapy plus placebo.

In the population studied, the addition of everolimus did not improve progression-free survival or overall survival, except in a small subset of patients. The study was stopped prematurely due to being under enrollment.

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research &mdash; Frankfurt, Germany, discusses the results of trial combining everolimus (Afinitor) with paclitaxel in the treatment of patients with gastric cancer.

Salah-Eddin Al-Batran, MD

Articles

Dr. Al-Batran on Future of Treatment in Gastric Cancer

Dr. Al-Batran on Paclitaxel Plus Everolimus in Gastric Cancer